Thyroid Gland Neoplasm

In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=… (full text at CIViC)

PMID 25024077 · Xing et al., 2014 · Open in CIViC

In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC)

PMID 18682506 · Elisei et al., 2008 · Open in CIViC

Clinical study including 219 patients with papillary thyroid cancer (PTC) to determine a correlation between the BRAF V600E mutation and poor oncological outcome. This study found that 107 of the 219 … (full text at CIViC)

PMID 16174717 · Xing et al., 2005 · Open in CIViC

BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.

PMID 21594703 · Howell et al., 2011 · Open in CIViC

BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.

PMID 21594703 · Howell et al., 2011 · Open in CIViC

BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.

PMID 24396464 · He et al., 2014 · Open in CIViC

V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).

PMID 21594703 · Howell et al., 2011 · Open in CIViC

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

A systematic review and meta-analysis of 34 studies comprising 978 patients with anaplastic thyroid carcinoma (ATC) reported a pooled prevalence of BRAF V600E of 33% (95% CI, 26%–40%). When cases with… (full text at CIViC)

PMID 39086414 · Behnagh et al., 2024 · Open in CIViC

Targeted next-generation sequencing of 11 anaplastic thyroid carcinomas (ATCs) with matched normal tissue identified BRAF V600E in 10 of 11 tumors (91%), making BRAF the most frequently mutated gene i… (full text at CIViC)

PMID 26980298 · Jeon et al., 2016 · Open in CIViC

Comprehensive genomic profiling of 68 anaplastic thyroid carcinomas (ATCs) identified BRAF alterations in 10.3% of tumors. BRAF mutations were more common in ATCs with a concurrent or prior papillary … (full text at CIViC)

PMID 40674659 · Trivedi et al., 2025 · Open in CIViC

In BRAF V600E-positive murine anaplastic thyroid carcinoma (ATC) cell lines (TBP-3743, TBPt-3403, and TBPt-3610R), treatment with the BRAF inhibitor PLX4720 decreased ERK phosphorylation and significa… (full text at CIViC)

PMID 24994118 · Vanden Borre et al., 2014 · Open in CIViC

In an orthotopic mouse model generated using BRAF V600E-positive 8505c anaplastic thyroid carcinoma cells, treatment with the selective BRAF V600E inhibitor PLX4720 decreased phospho-ERK1/2 expression… (full text at CIViC)

PMID 22202162 · Nehs et al., 2012 · Open in CIViC

In transgenic mice with thyroid-specific expression of BRAF V600E, Tg-BRAF2 mice developed papillary thyroid carcinoma (PTC) in 14 of 15 animals at 12 weeks and 13 of 14 animals at 22 weeks. These tum… (full text at CIViC)

PMID 15899815 · Knauf et al., 2005 · Open in CIViC

In a phase 2 trial, patients with radioiodine refractory papillary thyroid carcinoma harboring BRAF mutation were treated with dabrafenib alone or combination with trametinib. 94% patients havd BRAF V… (full text at CIViC)

Open in CIViC

Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anap… (full text at CIViC)

PMID 29072975 · Subbiah et al., 2018 · Open in CIViC

In this systematic review and meta-analysis, the authors evaluated the predictive relevance of the BRAF V600E variant in patients with anaplastic thyroid carcinoma (ATC) treated with MAPK pathway-targ… (full text at CIViC)

PMID 38709445 · Priantti et al., 2024 · Open in CIViC

In a phase 2 trial, patients with radioiodine refractory papillary thyroid carcinoma harboring BRAF mutation were treated with dabrafenib alone or combination with trametinib. 94% of patients had BRAF… (full text at CIViC)

Open in CIViC

In this retrospective, single-center, real-world study conducted between May 2018 and April 2022, 27 patients with anaplastic thyroid carcinoma (ATC) were stratified into three groups: patients with B… (full text at CIViC)

PMID 36651156 · da Silva et al., 2023 · Open in CIViC

This multi-institutional retrospective study analyzed 44 patients with anaplastic thyroid carcinoma (ATC) treated across three hospitals in Taiwan. BRAF mutation testing was performed in 24 patients (… (full text at CIViC)

PMID 36504909 · Chang et al., 2022 · Open in CIViC

In a single-center retrospective study of 10 patients with BRAF V600E-positive papillary thyroid carcinoma treated with dabrafenib plus trametinib, 5/10 patients (50%; 95% CI 24–76%) achieved an objec… (full text at CIViC)

PMID 40844731 · Ando et al., 2025 · Open in CIViC

In a single-center retrospective study of 6 patients with BRAF V600E-positive anaplastic thyroid carcinoma treated with dabrafenib plus trametinib, 4/6 patients (67%; 95% CI 24–94%) achieved an object… (full text at CIViC)

PMID 40844731 · Ando et al., 2025 · Open in CIViC

A 47-year-old woman with advanced metastatic anaplastic thyroid carcinoma (ATC) harboring a BRAF V600E mutation, identified by comprehensive genomic profiling of a resected lung metastasis, received c… (full text at CIViC)

PMID 27697975 · Agarwal et al., 2016 · Open in CIViC

This single-patient case report describes a 63-year-old woman diagnosed with BRAF V600E-mutated anaplastic thyroid carcinoma (ATC). Following multiple surgical resections, the patient developed recurr… (full text at CIViC)

PMID 37900238 · Lee et al., 2023 · Open in CIViC

An updated analysis of the phase 2 ROAR basket trial evaluating combination dabrafenib and trametinib in 36 BRAF V600E mutated anaplastic thyroid carcinoma patients (16 patients previously described i… (full text at CIViC)

PMID 35026411 · Subbiah et al., 2022 · Open in CIViC

In an in vitro study, K2, a papillary thyroid carcinoma cell line expressing the BRAFV600E mutation, was associated with sensitivity to dasatinib treatment. Sensitivity was determined by assessing cel… (full text at CIViC)

PMID 23729178 · Henderson et al., 2014 · Open in CIViC

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MAPK inhibitor CI-1040 than those with wildtype BRAF (IC50: 0.031-1.251 uM vs. 44.376-278.286 uM). In a mouse xenograft m… (full text at CIViC)

PMID 17911174 · Liu et al., 2007 · Open in CIViC

In a retrospective single-center cohort of patients with BRAF V600E-mutated anaplastic thyroid carcinoma, 30 patients treated with upfront dabrafenib, trametinib, and pembrolizumab had a significantly… (full text at CIViC)

PMID 38226606 · Hamidi et al., 2024 · Open in CIViC

Ghosh et al. provide compelling evidence that thyroid cancers with a BRAFV600E mutation are sensitive to combined PLX4720 and Ponatinib treatment. They predicted a synergistic effect using HTS of acti… (full text at CIViC)

PMID 31937621 · Ghosh et al., 2020 · Open in CIViC

Both in vitro and in vivo models in Kebebew et al. provide evidence that a combinatorial treatment of PLX4720 (a BRAF inhibitor) and ponatinib (a multi targeting tyrosine kinase inhibitor) shows poten… (full text at CIViC)

PMID 31937621 · Ghosh et al., 2020 · Open in CIViC

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC)

PMID 18682506 · Elisei et al., 2008 · Open in CIViC

Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MEK inhibitor RDEA119 than those with wildtype BRAF (IC50: 0.034-0.217 uM vs. 1.413-34.120 uM).

PMID 21351275 · Liu et al., 2010 · Open in CIViC

In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC)

PMID 18682506 · Elisei et al., 2008 · Open in CIViC

Following treatment with sorafenib, thyroid cancer cell lines with BRAF V600E mutations had severely reduced proliferation rates, but cells with wildtype BRAF were insensitive (P<0.0001).

PMID 16533790 · Salvatore et al., 2006 · Open in CIViC

Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positiv… (full text at CIViC)

PMID 27460442 · Brose et al., 2016 · Open in CIViC

Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort… (full text at CIViC)

PMID 27460442 · Brose et al., 2016 · Open in CIViC

In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete res… (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the … (full text at CIViC)

PMID 24987354 · Ali et al., 2014 · Open in CIViC

In an 80 year old female anaplastic thyroid cancer patient harboring BRAF V600E and TP53 E180K co-mutations, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification o… (full text at CIViC)

PMID 27532222 · Prager et al., 2016 · Open in CIViC